Kornimate/medical-research-clean huggingface dataset:
how breast conservative surgery (bcs) affects women's daily activities on post-operation 2 days?

Conditions: Breast Cancer

Summary: we revise 8 disability items from spadi into chinese to develop a simple self-completion questionnaire for the assessment of restriction in daily activities resulting from breast conservative surgery. the purpose of this study was to validate the score obtained from this questionnaire by testing restriction of shoulder active flexion and abduction on examination at post bcs 2 days correlates with disability score.

breast-conserving therapy (bct) is a breast cancer treatment using breast conservative surgery(bcs) with lymph node dissection and with or without following by radiotherapy(rt). (morrow,2004). results of bcts demonstrate high rates of local tumor control with satisfactory cosmetic results. (morrow,2004) nowadays, the local treatment of breast cancer has slowly accepted from radical mastectomy with lymph node dissection to (bct) in the last 100 years. (morrow,2004) after surgical intervention for breast cancer carcinoma, the most frequent morbilities are lymphedema of the unilateral upper extremity and shoulder dysfunction. (wingate l,1985; grube, 2004)from the perspective of the institute of medicine's(iom), the outcome measures shifts from the impairment-based measures to functional limitation measures. (jette am,1995) base on the third element in donabedian's framework of quality of physical therapy care, the determination of outcomes in terms of death, morbidity, disability, or quality of life. (jette am,1995)although shoulder active range-of-motion exercises could start at the day right after any type or level of lymph node dissections for breast cancer patients, (staradub vl, 2004;wingate l,1985) in my literature review results, no functional evaluation questionnaires that was sensitive enough to detect the disabilities resulting from lymph node dissections at post bcs 2 days. so we revise 8 disability items from spadi into chinese to develop a simple self-completion questionnaire for the assessment of restriction in daily activities resulting from breast conservative surgery. the purpose of this study was to validate the score obtained from this questionnaire by testing restriction of shoulder active flexion and abduction on examination at post bcs 2 days correlates with disability score.

Eligibility criteria:
inclusion criteria: * post breast conservative surgery 2 days * with lymph node dissection exclusion criteria: * total spadi score is not zero

Keywords: breast conservative surgery shoulder functional outcome questionnaire disability questionnaire
the effect of tele-nursing on parents of circumcised children

Conditions: Health Care Utilization; Nursing Caries

Summary: circumcision is applied in many regions of the world for cultural, social, religious and medical reasons. considering the frequency of circumcision in the world is 30%, this rate is close to 100% in turkey.

circumcision is applied in many regions of the world for cultural, social, religious and medical reasons. considering the frequency of circumcision in the world is 30%, this rate is close to 100% in turkey. it will be done to determine the effect of the tele-nursing service applied to the parents of circumcised children after discharge on the anxiety and care satisfaction of the parents. this study is planned to be carried out in bursa kestel state hospital, surgery service, between october 2022 and january 2024. this study will consist of a control and an experiment group. this study is planned to be done as a single blind randomised control trial and will use equal samples block randomisation design. the study is planned to carry out with 84 parents, 42 parents in each group.samples number is calculated via g-power pogramme. control grup: the control group in the study will be the parents of children who received routine care in the surgical service and had circumcision operation.after acceptance of the child's admission to the ward, parents will be asked to complete the beck anxiety scale. beck anxiety scale and health care satisfaction scale will be applied to the parents again after the discharge training given routinely in the service. control grup will be called on the postoperative 4th day after discharge and asked to fill in the beck anxiety scale and health care satisfaction scale. the intervention group: the intervention group: in the study will be the parents of children who received routine care in the surgical service and tele-nursing service, who had undergone circumcision operation.after the admission of the child in the service, the beck anxiety scale will be applied to measure the anxiety levels of the parents at the first hospitalization. after the routine discharge training in the service, the beck anxiety scale and health care satisfaction scale will be applied to the parents again. then, the parents will be called on the 1st postoperative day and training will be provided. on the postoperative 2nd, 3rd and 4th days, counseling will be provided. on the postoperative 4th day parents will be asked to fill in the beck anxiety sscale and health care satisfaction scale.

Eligibility criteria:
inclusion criteria: * parents whose children will be circumcised, * at least one parent as a caregiver during the surgical process, * parents who are able to read and write -parents have no communication problems, - * parents who can access a smartphone, exclusion criteria: * parents who have a childs with a special condition who has difficulties in understanding and perceiving

Keywords: health care care satisfaction tele nursing anxiety circumcision
a study to assess the cholesterol lowering effect of an ezetimibe/simvastatin combination tablet compared to another cholesterol lowering drug in patients with high cholesterol and with high cardiovascular risk (0653a-809)(completed)

Conditions: Hypercholesterolemia

Summary: this is a multicenter study to evaluate the safety and efficacy of ezetimibe/simvastatin versus rosuvastatin in participants with high cholesterol.


Eligibility criteria:
inclusion criteria: * participant is currently taking a statin medication for the treatment of high cholesterol * participant has an ldl-c level that is greater than or equal to 100 mg/dl and less than or equal to 190 mg/dl exclusion criteria: * women who are pregnant or nursing, or women who intend to become pregnant * participant has any condition, situation, or is currently taking any medication that might pose a risk to the participant or interfere with participation in the study

Keywords: high cholesterol
a study to compare the amount of premarin components that is absorbed into the blood of japanese healthy postmenopausal women following oral administration of two different tablets of premarin under fast and fed conditions.

Conditions: Primary Ovarian Insufficiency; Vaginitis; Metrorrhagia; Menopause

Summary: the purpose of this study is to assess the bioequivalence and food effect for a new premarin formulation compared with a premarin reference tablet in japanese healthy postmenopausal women.


Eligibility criteria:
inclusion criteria: * japanese healthy postmenopausal women exclusion criteria: * history or current evidence of thrombophlebitis, thromboembolic disorders, or any coagulopathies. * history or presence of malignancy or estrogen-dependent neoplasia. subjects with a documented history of any malignancy, except for basal or squamous cell carcinoma of skin, which has been treated and fully resolved for a minimal 5 years. * history or presence of benign or malignant liver tumor that developed during the use of oral contraceptives or other estrogen-containing products.

Keywords: bioequivalence menometrorrhagia climacteric disturbance estrogen replacement therapy estrogens conjugated
special investigation of long term use of sertraline.

Conditions: Depression; Panic Disorder

Summary: special investigation of long term use of sertraline, 52 week observation, long-term safety. the objective of this "special investigation" is to collect information about 1) adverse drug reactions not expected from the lpd (unknown adverse drug reactions), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug regarding long time use.

all the patients for whom an investigator prescribes the first sertraline hydrochloride should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Eligibility criteria:
inclusion criteria: the patients who take sertraline hydrochloride for longer than the duration of 16 weeks among the patients enrolled in a0501090 (drug use investigation of j zoloft). exclusion criteria: patients not taking sertraline hydrochloride.
retrospective analysis of veritas in breast reconstruction

Conditions: Seroma; Necrosis; Infection

Summary: retrospective data collection of the use of veritas in breast reconstruction surgery

this is a multi-center study to retrospectively collect data on the use of veritas collagen matrix in breast reconstruction. data will be collected on post-operative complications in immediate breast reconstruction and then be compared to literature reported post-operative complication rates associated with the use of acellular dermal matrix in immediate breast reconstruction.

Eligibility criteria:
inclusion criteria: * age 18 years or older * patients who underwent mastectomy with immediate breast reconstruction using veritas collagen matrix * patients who underwent mastectomy with single stage procedures or two-stage procedures using veritas collagen matrix exclusion criteria: * patients who underwent delayed breast reconstruction * reconstruction with something other than veritas collagen matrix * breasts that were created with diep or tram procedures
vinorelbine metronomic chemotherapy combined with hypofractionated radiotherapy, pd-1/pd-l1 sequential gm-csf and il-2 for treatment of advanced refractory non-small cell lung cancer and breast cancer(prag 6.0)

Conditions: Carcinoma, Non-Small-Cell Lung; Carcinoma Breast

Summary: this is an open-label, single-arm, phase ii investigator-initiated trial of vinorelbine metronomic chemotherapy combined with hypofractionated radiotherapy, pd-1/pd-l1 inhibitor sequential gm-csf and il-2 for treatment of advanced refractory non-small cell lung cancer and breast cancer.


Eligibility criteria:
inclusion criteria: 1. aged 18 years and above; 2. diagnosed with histologically or cytologically-confirmed, standard treatment is ineffective (disease progresses after treatment) or locally advanced or metastatic malignant non-small cell lung cancer and breast cancer patients who cannot tolerate standard therapy, cannot receive or do not have standard therapy; 3. ecog(eastern cooperative oncology group) performance is 0-3; 4. life expectancy greater than 3 months; 5. t lymphocyte absolute value ≥0.5 upper limit of normal (uln), absolute neutrophil count(anc)≥1.0 x 10(9)/l#serum aspartate transaminase (ast) and serum alanine transaminase (alt) ≤3.0\*uln, or ast and alt≤5\*uln with hepatic metastasis; total serum creatinine ≤1.5\*uln# 6. signed informed consent form# - exclusion criteria: 1. current pregnancy or lactation# 2. history of other malignant tumors within 5 years prior to dose administration, expect for#malignancies that can be cured after treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer); 3. uncontrolled epilepsy, central nervous system diseases or mental illness; 4. currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, or greater than or equal to class 2 congestive heart failure as defined by the new york heart association functional classification, or history of myocardial infarction unstable angina, or acute coronary syndrome within 6 months prior to enrollment in the study; 5. received allogeneic hematopoietic stem cell transplantation or solid organ transplantation; 6. other serious, uncontrolled concomitant diseases that may affect protocol compliance or interpretation of outcomes, including active opportunistic infections or advanced (severe) infections, uncontrolled diabetes; 7. allergic to any of the ingredients used in the study; 8. a history of immunodeficiency, including hiv positive or other acquired or congenital immunodeficiency disease, or a history of organ transplantation, or other immune-related disease requiring long-term oral hormone therapy; 9. acute and chronic tuberculosis infection; 10. other disorders with clinical significance according to the researcher's judgment. -
the prospective segeberg registry for coronary chronic total occlusions (cto)

Conditions: Coronary Chronic Total Occlusions

Summary: a prospective follow-up assessment in bad segeberg with patients undergoing recanalization for coronary chronic total occlusion lesion/s

a prospective single center registry including all patients treated for chronic total occlusion coronary lesion/s at the heart center, bad segeberg, germany. patients undergo a routine clinical follow-up schedule, including a long-term follow-up.

Eligibility criteria:
inclusion criteria: * patients with coronary chronic total occlusions undergoing recanalization via percutaneous coronary interventions exclusion criteria: * none

Keywords: chronic total occlusion
adherence in pediatric multiple sclerosis

Conditions: Multiple Sclerosis

Summary: disease modifying therapies (dmt) are widely used for children and adolescents with ms. nonetheless, many pediatric patients continue to relapse and therefore require changes in therapy. we designed this research study to learn more about medication use in children and adolescents with ms. we are also interested in learning what a behavioral feedback intervention can tell us about adherence to medicine. finally, we hope this research project will inform the way we provide clinical care for children and adolescents with ms.


Eligibility criteria:
inclusion criteria: * adolescent boys/girls who are 10 to 17 years 11 months old; * have a diagnosis of ms, as per revised mcdonald diagnostic criteria and international pediatric ms study group criteria; * prescribed with an oral or injectable disease-modifying therapy for ms for at least six months. exclusion criteria: * have non-specific white matter abnormalities and metabolic or infectious etiologies for white matter abnormalities. this is indicative of not having a true diagnosis of ms. * patients on iv dmt will not be included in the study. * non-english speaking patients
closure of patent ductus arteriosus with indomethacin or ibuprofen in extreme low birth weight infants

Conditions: Patent Ductus Arteriosus

Summary: pharmacological closure of ductus arteriosus with prostaglandin (pg) inhibitors has been used for years. previous studies indicated that ibuprofen has similar effect on ductal closure as indomethacin but has less adverse effects on renal function, cerebral blood flow and mesenteric blood flow.1-7 there are, however, very few studies being done specifically on extremely low birth weight (elbw) infant \< 1000 g. this group of infants has immature kidney and often has poor response to pg inhibitors and has high mortality and morbidity. we hypothesized that, in elbw infants, the ductal and renal response to pg inhibitors may be different between indomethacin and ibuprofen.

the aims of this study are to compare the efficacy, the side effects and the renal prostaglandin (pg) excretion between indomethacin and ibuprofen in extremely low birth weight (elbw) infants. we enrolled one hundred and ten elbw infants who had clinically significant and echo-evidence patent ductus arteriosus were assigned into 2 groups, 56 received indomethacin (0.2 mg/kg, 0.1 mg/kg and 0.1 mg/kg in 24 hours interval) and 54 received ibuprofen (10 mg/kg, 5mg/kg and 5 mg/kg in 24 hours interval). serum electrolytes, creatinine, renal function (urine output, glomerular filtration rate (gfr), fractional excretion of sodium and potassium, osmolar clearance and free water clearance), urinary pg excretion, pulmonary outcome and mortality were all evaluated.

Eligibility criteria:
inclusion criteria: * the selection criteria were: (1) preterm infants with birth weight \<1000 g; 2) radiographic diagnosis of respiratory distress syndrome (rds); (3) requirement of mechanical ventilation and (4) echocardiographic and clinical evidence of significant patent ductus arteriosus (pda). exclusion criteria: * exclusion criteria included: (1) evidence of infection or sepsis; 2) lethal congenital anomalies; (3) oliguria (\ 2.0 mg/dl and (4) low platelet count (\< 50,000/mm3) or bleeding tendency.

Keywords: bronchopulmonary dysplasia patent ductus arteriosus prostaglandin respiratory distress syndrome
evaluation of the prophylactic use of mitomycin c 0.02% to inhibit haze formation after photorefractive keratectomy for high myopia: 15 x 30 seconds

Conditions: High Myopia

Summary: to evaluate and compare the effect of the prophylactic use of two different exposure times of mitomycin c (mmc) 0.02% to inhibit haze formation after photorefractive keratectomy (prk) for high myopia (\> -7.0 d). methods: forty six eyes of twenty three patients, 8 men and 15 women, with high myopia were included in this prospective study. mean age at the time of prk plus mmc was 31.7 years. before prk, the mean spherical equivalent was -8.50 d (range, -7.25 to -10.50 d). in each patient, one eye was randomly assigned to prk and a single intraoperative topical application of mitomycin c 0.02% for 15 seconds (group 1) and the fellow eye, for 30 seconds (group 2).the inclusion criteria were high myopia, no central corneal opacity and inadequate corneal thickness to allow a safe laser in situ keratomileusis procedure. refraction, uncorrected visual acuity, best spectacle-corrected visual acuity (bscva), and slit-lamp evidence of corneal opacity (haze) were evaluated over 12 months


Eligibility criteria:
inclusion criteria: * myopia or compound myopic astigmatism * stable refractive error * no associated eye disease exclusion criteria: * diabetes, * autoimmune diseases * topographic abnormalities

Keywords: myopia mitomycin
predictive values of serotonergic alterations for outcome - 2

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to evaluate the predictive value of serotonergic alterations for outcome.


Eligibility criteria:
please contact site for information.

Keywords: cocaine dependence
efficacy of magnetotherapy in hand erosive osteoarthritis.

Conditions: Musculoskeletal Disease; Musculoskeletal Pain; Physical Therapy

Summary: erosive arthritis (ea) is an unusual pathology. there is no definitive treatment and the conventional one has little efficacy. despite using magnetotherapy (mgt) as a treatment, there is no evidence supporting its use.

the aim of the study is to evaluate the efficacy of mgt in patients suffering from hand ea, compared to placebo, in terms of pain (assessed by visual analog scale (vas)) and functionality (assessed by the disabilities of the arm, shoulder and hand (dash) score) during the treatment and after a 3-months period. secondarily, rigidity (modified kapandji index), grip strength (jamar dynamometry) and quality of life (sf-36 questionnaire) were assessed. treatment safety will also be evaluated.

Eligibility criteria:
inclusion criteria: * patients of both sexes older than 18 years with symptomatic hand erosive osteoarthritis for more than 6 months. * patients receiving treatment or not for their hand pathology. * patients suffering from hand chronic pain due to their pathology and scoring vas equal or greater than 4/10. * patients who voluntarily signed the informed consent and agree to participate in the study. exclusion criteria: * pregnancy * patients with pacemaker or similar devices * pacients with cognitive dysfunction. * patients with psychiatric pathologies unable to comply with the treatment and follow-up * patients with active oncological and / or infectious pathology * patients with previous magnetotherapy or paraffin treatment in the last year

Keywords: erosive arthritis hands arthritis magnetotherapy
comparison of two steroid regimens to prevent transplant rejection after corneal transplant (dmek)

Conditions: Fuchs' Dystrophy; Bullous Keratopathy

Summary: the purpose of this study is to compare two different commonly used steroid dosing regimens after descemet's membrane endothelial keratoplasty (dmek) transplant surgery. the investigators hope to determine if one is more effective at preventing rejection or if both are equally effective.

graft rejection is one of the leading causes of cornea transplant failure. to help prevent rejection, corticosteroid eye drops are used after transplant surgery. the steroid eye drop dosing regimen varies from surgeon to surgeon, because no studies have been done to determine the optimum dosing regimen.

Eligibility criteria:
inclusion criteria: the following are requirements for inclusion in the study: * male or female patient, at least 18 years of age, who is a candidate for dmek due to corneal endothelial dysfunction or who has undergone dmek within the last 7 weeks * patient is able and willing to administer eye drops. * patient is able to comprehend and has signed the informed consent form. * patient is likely to complete the entire one-year course of the study. * patient has best corrected visual acuity (bcva) of at least 20/200 in the fellow eye. * corneal neovascularization will not be judged as an exclusion criteria for the study exclusion criteria: the following are exclusion criteria for patients in this study: * a patient with a previous failed graft in the study eye with a history of a prior rejection episode * a patient exhibiting any intraocular inflammation * a patient with a known sensitivity to any of the ingredients in the study medications * a patient who has a condition (i.e., uncontrolled systemic disease) or is in a situation which in the investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study * a patient with abnormal eyelid function * a patient that is exhibiting active corneal ulceration, keratitis, or conjunctivitis, or who has a history of herpetic keratitis * a patient with the presence of any ocular disease that would interfere with the evaluation of the study treatment * a patient with a history of non-compliance with using prescribed medication * a patient who is concurrently involved in or participated in another clinical trial within 30 days prior to enrollment in this study.

Keywords: dmek rejection corticosteroid